Chemical Biology Facility (ChBF) The Chemical Biology Facility (ChBF) is a major, cancer-focused component of the University of Pittsburgh Drug Discovery Institute (UPDDI) with the following Specific Aims: 1) provide assistance to designing, developing, and implementing cost effective screening assays as well as access to large compound libraries for probe and lead identification. This includes assisting with early toxicity assays for profiling compounds; 2) guide collaborators in designing effective drug discovery projects/programs for the discovery of novel cancer therapeutics; and 3) provide access to the state-of-the-art use of QSP in implementing novel drug discovery campaigns. The ChBF provides guidance on designing and executing drug discovery and development projects from target and lead discovery through preclinical development. The ChBF provides support services to UPCI researchers for: 1) high throughput screening and high content screening assay design, development, validation, and implementation; 2) lead characterization and optimization including early safety assessment; 3) data analysis; 4) accessing companion diagonstic opportunities; 5) assisting investigators in establishing connections with pharmaceutical companies; and 6) designing comprehensive drug discovery/development programs. The ChBF has added several early safety assessment assays to its armamentarium to aid researchers in the early triage of compounds during drug development including a zebrafish cardiotox assay, liver toxicity assay, and a microsomal stability assay. We have also implemented zebrafish imaging assays to enable higher throughput vertebrate models for drug discovery and development, as well as tissue engineered, human 3-D, biomimetic models (e.g. liver). A key addition made to the ChBF services is the implmentation of Quantitative Systems Pharmacology (QSP) as a new approach to drug discovery. QSP is an approach to drug analysis and development that combines computational and experimental methods to elucidate, validate, and apply new pharmacological concepts to the development and use of therapeutics. Additionally, the ChBF has developed and implemented methods to assess heterogeneity in biological systems to help researchers better understand the activity of compounds in their models. During the current project period investigators in 8 of the UPCI Research Programs used the ChBF.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-31
Application #
9753964
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
31
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications